Ankr Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 41)
Ankr Health logo

Ankr Health

EmergingHealthcare

General

San Francisco AI that virtualizes clinic front desk, medical assistant, and scribe functions for on-demand virtual clinics; YC-backed at $2.3M revenue with EHR integration generating $1M new revenue for average clinic.

AI VisibilityBeta
Overall Score
C41
Category Rank
#345 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
46
Perplexity
41
Gemini
36

About

Ankr Health is a San Francisco-based healthcare technology company using generative AI to virtualize clinic infrastructure — automating front desk operations, medical assistant workflows, and clinical documentation (AI scribe functions) that enable physicians to launch on-demand virtual and hybrid clinics without the full overhead of physical clinic staff. Founded in 2022 and backed by Y Combinator with $500,000 raised from MedTech Innovator, WorldQuant Ventures, and YC, Ankr Health generated $2.3 million in revenue in 2024 with a 15-person team, with integration across all major EHR systems (Epic, Cerner, athenahealth) and a reported $1 million in new annual revenue generated for average clinic customers.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

41
Overall Score
93
#345
Category Rank
#1
77
AI Consensus
80
stable
Trend
stable
46
ChatGPT
94
41
Perplexity
89
36
Gemini
94
41
Claude
92
38
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.